Eleven infants with RDS, 6 treated with intravenous fluids and 5 treated with intravenous fluids plus SKA fibrinolysin, are presented. The mortality rates were 17% (1/6) in the group receiving only intravenous fluids and 100% (5/5) in the group receiving intravenous fluids and intravenous SKA fibrinolysin. Combining the 8 infants treated with intravenous SKA fibrinolysin reported by Ambrus et al. with the present series, a mortality rate of 87% (11/13) was obtained. The intravenous administration of SKA fibrinolysin would appear to be contraindicated in the treatment of RDS in premature infants since its use has been associated with a significantly increased mortality rate—a mortality rate which makes the risk of further trials highly prohibitive.
Skip Nav Destination
Experience and Reason—Briefly Recorded| December 01 1964
The Use of Fibrinolysin in the Treatment of Respiratory Distress Syndrome
MANUEL F. GOMEZ;
Pediatrics (1964) 34 (6): 877–880.
- Views Icon Views
- Share Icon Share
- Search Site
MANUEL F. GOMEZ, STANLEY N. GRAVEN; The Use of Fibrinolysin in the Treatment of Respiratory Distress Syndrome. Pediatrics December 1964; 34 (6): 877–880. 10.1542/peds.34.6.877
Download citation file: